Takahiro Tsujimura
Overview
Explore the profile of Takahiro Tsujimura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
338
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakazawa T, Morimoto T, Maeoka R, Yamada K, Matsuda R, Nakamura M, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892084
Enhancing immune cell functions in tumors remains a major challenge in cancer immunotherapy. Natural killer cells (NK) are major innate effector cells with broad cytotoxicity against tumors. Accordingly, NK cells...
2.
Morimoto T, Nakazawa T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, et al.
Regen Ther
. 2024 Feb;
25:367-376.
PMID: 38405180
Introduction: Innate immune cells are important in tumor immunotherapy. Natural killer cells (NKCs) are also categorized as innate immune cells and can control tumor growth and metastatic spread. Glioblastoma (GBM)...
3.
Morimoto T, Nakazawa T, Matsuda R, Maeoka R, Nishimura F, Nakamura M, et al.
Int J Mol Sci
. 2024 Feb;
25(4).
PMID: 38397112
Despite standard multimodality treatment, containing maximum safety resection, temozolomide, radiotherapy, and a tumor-treating field, patients with glioblastoma (GBM) present with a dismal prognosis. Natural killer cell (NKC)-based immunotherapy would play...
4.
Maeoka R, Nakazawa T, Matsuda R, Morimoto T, Shida Y, Yamada S, et al.
Int J Mol Sci
. 2023 Sep;
24(18).
PMID: 37762486
Glioblastoma (GBM) is the leading malignant intracranial tumor, where prognosis for which has remained extremely poor for two decades. Immunotherapy has recently drawn attention as a cancer treatment, including for...
5.
Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, et al.
J Exp Clin Cancer Res
. 2023 Aug;
42(1):205.
PMID: 37563692
Background: Glioblastoma (GBM) is the most common malignant brain tumor and has "immunologically cold" features. Changing GBM to an "immunologically hot" tumor requires a strong trigger that induces initial immune...
6.
Nakazawa T, Maeoka R, Morimoto T, Matsuda R, Nakamura M, Nishimura F, et al.
Regen Ther
. 2023 Jun;
24:32-42.
PMID: 37303464
Introduction: Natural killer cells (NKCs) are immune cells that can attack cancer cells through the direct recognition of ligands without prior sensitization. Cord blood-derived NKCs (CBNKCs) represent a promising tool...
7.
Morimoto T, Nakazawa T, Maeoka R, Nakagawa I, Tsujimura T, Matsuda R
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36768432
Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults. Despite multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, the median overall survival (OS)...
8.
Nakazawa T, Maeoka R, Morimoto T, Matsuda R, Nakamura M, Nishimura F, et al.
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36361783
Irradiated murine induced-pluripotent stem cells (iPSCs) elicit the antitumor response in vivo. However, it is unclear whether human iPSCs would elicit antitumor effects. In the present study, we investigated the...
9.
Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, et al.
Regen Ther
. 2022 Aug;
21:185-191.
PMID: 35919498
Introduction: Cell-based immunotherapy is categorized as a regenerative therapy under the Regenerative Medicine Safety Act in Japan. Natural killer (NK) cell-based immunotherapy is considered a promising strategy for treating cancer,...
10.
Morimoto T, Nakazawa T, Matsuda R, Nishimura F, Nakamura M, Yamada S, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638384
Glioblastoma (GBM) is the most common and aggressive primary brain tumor, with a dismal prognosis. Natural killer (NK) cells are large granular lymphocytes with natural cytotoxicity against tumor cells, and...